Meeting on the Mesa 2021 | The future of gene therapies for the eye

Sue Washer, Applied Genetic Technologies Corporation, Alachua, FL, discusses future advancements within the field of ophthalmology gene therapies. With the advent of voretigene neparvovec, the first approved gene therapy for retinal diseases, the future of gene therapies treating vision loss is promising. Adeno-associated viruses (AAVs) additionally have potential uses other than as a vector, including delivering RNA and CRISPR-Cas 9 therapies. This interview took place at Meeting on the Mesa 2021.